Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

Table of Contents

February 1, 2021; Volume 62,Issue 2

Cover image

Cover image expansion

FEATURED ARTICLE

18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2– Metastatic Breast Cancer. Lanell Peterson et al. See page 184.

Increasing tumor immunogenicity: combined 225Ac-PSMA–targeted radionuclide and immune therapies in prostate cancer. Johannes Czernin et al. See page 228.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer
  • Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
Sign up for alerts

Jump to

  • This Month in JNM
  • Editor's Page
  • Discussions with Leaders
  • The State of the Art
  • Editorial
  • Hot Topics
  • Focus on Molecular Imaging
  • Continuing Education
  • Oncology
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
      • BRIEF COMMUNICATION
    • Basic
  • Theranostics
    • Clinical
    • Basic
      • BRIEF COMMUNICATION
  • Neurology
    • Clinical
    • Basic
  • Infectious Disease and Inflammation
    • Clinical
  • Radiobiology/Dosimetry
    • Clinical
  • Molecular Imaging
    • Basic
  • Physics and Instrumentation
    • Clinical
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
  • Deep Learning Analysis of Upright-Supine High-Efficiency SPECT Myocardial Perfusion Imaging for Prediction of Obstructive Coronary Artery Disease: A Multicenter Study
  • Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region
  • Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
  • Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
More...
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire